BMS-986251

selective RORgt inverse agonist

entered clinical dev. (psoriasis), discontinued

from HTS and SBDD

ACS Med. Chem. Lett., Apr. 10, 2020

Bristol Myers Squibb, Princeton, NJ

BMS-986251 is an inverse agonist of RORgt, a hot target in inflammation for a significant period. Unfortunately it looks like development hit a wall in this space, and several publications…


 become a member to continue reading

Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.

  • Stay up-to-date and save more time with exclusive members-only content
  • On-board new team members with educational content and case studies
  • Generate ideas and discussion with easy-to-read slide decks
  • Generate ideas and discussion with easy-to-read slide decks